We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+20.7%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$52.6M
Cap. Flow
-$58.3M
Cap. Flow %
-54.02%
Top 10 Hldgs %
66.44%
Holding
50
New
11
Increased
11
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
LAB icon
Standard BioTools
LAB
+$4.55M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$2.58M
3
INCY icon
Incyte
INCY
+$2.52M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.94M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.81M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$71.4M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$4.29M
3
MRUS
Merus
MRUS
+$1.93M
4
KALV
KalVista Pharmaceuticals
KALV
+$1.13M
5
OCS icon
Oculis Holding
OCS
+$989K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
26
Neumora Therapeutics
NMRA
$302M
$871K 0.81%
+63,315
New +$1.02M
CABA icon
27
Cabaletta Bio
CABA
$455M
$804K 0.75%
47,150
– –
TRDA icon
28
Entrada Therapeutics
TRDA
$267M
$695K 0.64%
49,082
– –
BMEA icon
29
Biomea Fusion
BMEA
$91.3M
$598K 0.55%
40,000
– –
LONA
30
LeonaBio Inc
LONA
$72.1M
$493K 0.46%
18,000
– –
TRML
31
DELISTED
Tourmaline Bio
TRML
$481K 0.45%
+20,987
New +$740K
ALXO icon
32
ALX Oncology
ALXO
$290M
$468K 0.43%
41,950
– –
IMCR icon
33
Immunocore
IMCR
$1.73B
$439K 0.41%
+6,750
New +$463K
KYMR icon
34
Kymera Therapeutics
KYMR
$8.94B
$437K 0.41%
+10,875
New +$389K
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
$367K 0.34%
+7,450
New +$344K
ROIV icon
36
Roivant Sciences
ROIV
$26.2B
$342K 0.32%
+32,470
New +$350K
DBVT
37
DBV Technologies
DBVT
$847M
$278K 0.26%
37,095
– –
RVMD icon
38
Revolution Medicines
RVMD
$44B
$235K 0.22%
+7,300
New +$216K
ABCL icon
39
AbCellera Biologics
ABCL
$2.12B
$231K 0.21%
50,971
+38,450
+307% +$196K
AFMD
40
DELISTED
Affimed
AFMD
$197K 0.18%
37,247
– –
BCRX icon
41
BioCryst Pharmaceuticals
BCRX
$2.4B
$187K 0.17%
36,847
+19,000
+106% +$107K
KOD icon
42
Kodiak Sciences
KOD
$2.84B
$168K 0.16%
31,922
+12,300
+63% +$60.3K
IMTX icon
43
Immatics
IMTX
$1.32B
$165K 0.15%
+15,700
New +$183K
KYNB
44
Kyntra Bio
KYNB
$29.4M
$146K 0.14%
2,484
– –
GRTX
45
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$85.9K 0.08%
613,223
– –
ARGX icon
46
argenx
ARGX
$54.1B
– –
-1,430
Closed -$544K
CERS icon
47
Cerus
CERS
$474M
– –
-14,172
Closed -$30.6K
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-225,688
Closed -$71.4M
SLGC
49
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-1,696,558
Closed -$4.29M
EAR
50
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-147,904
Closed -$383K
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q1 2024 Portfolio in Review

As of Q1 2024, Nan Fung Group Holdings held 50 positions worth $108M, down 33% from $161M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Nan Fung Group Holdings withdrew a net $58.3M in Q1 2024, closing 5 positions and reducing 3 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $71.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Nan Fung Group Holdings opened a new position in Standard BioTools worth $5.1M.

  • Nan Fung Group Holdings's largest Q1 2024 buy was Standard BioTools: 1,883,179 shares worth $5.1M.
  • Nan Fung Group Holdings added most to Incyte in Q1 2024, an estimated $2.52M increase.
  • Nan Fung Group Holdings's biggest Q1 2024 reduction was Merus, cutting an estimated $1.93M.
  • Nan Fung Group Holdings fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $71.4M.
  • Nan Fung Group Holdings's ten largest holdings make up 66% of its $108M portfolio in Q1 2024.
  • Nan Fung Group Holdings opened 11 new positions and closed 5 in Q1 2024.
  • Nan Fung Group Holdings's portfolio value fell 33% quarter-over-quarter to $108M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2024, filed 14 May 2024.